Seda Beyhan Sagmen

Seda Beyhan Sagmen

Auto-generated profile, based on publicly available information

Seda Beyhan Sagmen

Health Science Unv Kartal Dr. Lutfi Kirdar Training and Research Hospital, Department of Pulmonary Medicine, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Archivos de Bronconeumología
Verified
Journal Article
Closed access
SBSeda Beyhan-Sagmen
Seda Beyhan-Sagmen
ÖBÖzgür BAYKAN
Özgür BAYKAN
BBBaran Balcan
Baran Balcan
BCBerrin Ceyhan
Berrin Ceyhan

16 March 2023 in Journal of Asthma
Verified
Journal Article
Closed access
SSSeda Beyhan Sagmen
Seda Beyhan Sagmen
BEBerrin Zinnet Eraslan
Berrin Zinnet Eraslan
EDErsin Demirer
Ersin Demirer
NKNesrin Kiral
Nesrin Kiral
SCSevda Comert
Sevda Comert
Maximum mid-expiratory flow (MMEF) is one of the pulmonary function tests that report small airway disease. Our study aimed to investigate the role of MMEF values in asthma control, the prevalence ...

27 August 2019 in Acta Haematologica
Verified
Journal Article
Closed access
PDF file
SSSeda Beyhan Sagmen
Seda Beyhan Sagmen
SCSevda Comert
Sevda Comert
EEEsra Turan Erkek
Esra Turan Erkek
AUAysun Küçüköz Uzun
Aysun Küçüköz Uzun
CDCoşkun Doğan
Coşkun Doğan
EPElif Torun Parmaksız
Elif Torun Parmaksız
Aim: Bleomycin is an antitumor antibiotic used successfully to treat a variety of malignancies, predominantly germ cell tumors and Hodgkin’s lymphoma (HL). The major limitation of bleomycin therapy is the potential for life-threatening interstitial pulmonary fibrosis. Early identification of asymptomatic patients who may develop toxicity is important. We aimed to evaluate fluorodeoxyglucose positron-emission tomography (FDG-PET/CT) findings to predict bleomycin toxicity (BT) early after chemotherapy with doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy before clinical symptoms and radiological changes occur. Materials and Methods: HL patients who were treated with ABVD were evaluated. SUVmax values of lung parenchyma were analyzed in FDG-PET/CT at diagnosis and after 4 cycles of chemotherapy in all patients. At the end of the chemotherapy cycles, lung parenchymal SUVmax values of patients with BT and without BT were compared statistically. Results: Twenty (66.7%) male and 10 (33.3%) female patients with HL were included. Five (16.7%) HL patients developed BT. In 3 HL patients, BT was determined after 5 cycles and in 2 patients, BT was seen after 6 cycles. In all 5 of these patients with BT, FDG uptake in PET-CT was increased after 4 cycles of chemotherapy and BT was predicted before clinical and radiological findings by FDG-PET/CT. After 4 cycles of chemotherapy, lung parenchymal SUVmax of patients with BT (3.24 ± 0.76) was significantly higher than in patients without toxicity (1.84 ± 0.52) (p < 0.001). In patients with BT, a significant increase was established in lung parenchymal SUVmax after 4 cycles of chemotherapy when compared to the time of diagnosis (p = 0.043). Conclusion: BT can be fatal. Early detection of BT is essential in clinical practice. FDG-PET/CT can predict BT before clinical and radiological findings occur.

6 December 2024 in Biomolecules and Biomedicine
Verified
Journal Article
Open access
PDF file
BEBerrin Zinnet Eraslan
Berrin Zinnet Eraslan
SCSümeyye Kodalak Cengiz
Sümeyye Kodalak Cengiz
OIOzlem Saniye İçMeli
Ozlem Saniye İçMeli
SSSeda Beyhan Sagmen
Seda Beyhan Sagmen
SCSevda Şener Cömert
Sevda Şener Cömert
The red cell distribution width (RDW)/albumin ratio (RAR) is an inflammation-based prognostic biomarker. To date, its prognostic value in patients with pulmonary thromboembolism (PTE) has been investigated in only one study. This study aimed to assess the effect of RAR on mortality in patients with PTE. Patients admitted for PTE between 2017 and 2023 were retrospectively reviewed. The data collected included demographic information, comorbidities, clinical findings, RDW, albumin, troponin, D-dimer levels, and in-hospital and 30-day mortality outcomes. RAR was calculated by dividing the RDW by albumin. A total of 190 patients were included in the study, of whom 83 (43.7%) were male. The mean age was 63 years (range: 23–89), and the mean RAR was 4.48% ± 1.68% /g/dL. A positive correlation was observed between RAR and both age and troponin level, whereas inverse correlations were noted with systolic blood pressure (sBP), diastolic blood pressure (dBP), and oxygen saturation (SpO2). Using a cutoff value of 5.294 determined by ROC analysis, patients with RAR ≥ 5.294 had a significantly shorter mean survival time than those with RAR value < 5.294 (16.310 months vs 35.163 months; log-rank test, P < 0.001). Multivariate Cox regression analysis identified malignancy (hazard ratio [HR], 4.213; 95% confidence interval [CI], 1.103–16.090; P = 0.035) and RAR (HR: 1.295, 95% CI: 1.035–1.621, P = 0.024) as independent predictors of survival. In conclusion, an RAR value ≥ 5.294 was associated with significantly shorter survival, underscoring its potential utility as a prognostic marker in clinical practice for non-massive PTE.


8 January 2025 in The Egyptian Journal of Bronchology
Verified
Journal Article
Open access
PDF file
SSSeda Beyhan Sağmen
Seda Beyhan Sağmen
CDCoşkun Doğan
Coşkun Doğan
SCSevda Cömert
Sevda Cömert
NKNesrin Kıral
Nesrin Kıral
EPElif Torun Parmaksız
Elif Torun Parmaksız
SGSule Karabulut Gul
Sule Karabulut Gul
Background: As in numerous cancers, the connection between the Ki-67 proliferation index and response to treatment in cellular breakdown in the lungs is underlined. The purpose of this study was to investigate the connection between the Ki-67 proliferation index and radiotherapy’s therapeutic and survival effects in small cell lung cancer. Methods: The limited-stage small cell lung cancer patients in our hospital were retrospectively reviewed. Patients receiving standard chemoradiotherapy were included in the study. Age, sex, cancer stage, comorbidities, response to treatment, and survival time were recorded. Bronchoscopic or transthoracic lung biopsy specimens which were taken at the time of diagnosis were stained with the Ki-67 immunohistochemical stain. Survival of patients and treatment response were compared statistically with the Ki-67 values. Results: The Ki-67 proliferation index (62.29 ± 7.52) was lower in patients with partial response than in patients with complete response (77.08 ± 2.84) (p < 0.001). When the correlation between survival time and Ki-67 was examined, there was a positive correlation between the Ki-67 and survival time (p: 0.019; r: 0.426). The patients were divided into two groups: Ki-67 < 68.70 and Ki-67 ≥ 68.70. In patients with Ki-67 ≥ 68.70, the survival rate was better than that of patients with Ki-67 < 68.70 (p: 0.012). In Cox regression analysis, Ki-67 PI < 68.7 was found that increased mortality by 2742 times independently. Conclusions: Patients with a high Ki-67 had a better survival effect than those with low Ki-67, and patients with complete responses had a higher Ki-67 value.